PMID- 29524402
OWN - NLM
STAT- MEDLINE
DCOM- 20180503
LR  - 20220330
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 498
IP  - 3
DP  - 2018 Apr 6
TI  - Ghrelin promotes human non-small cell lung cancer A549 cell proliferation through 
      PI3K/Akt/mTOR/P70S6K and ERK signaling pathways.
PG  - 616-620
LID - S0006-291X(18)30505-9 [pii]
LID - 10.1016/j.bbrc.2018.03.031 [doi]
AB  - Ghrelin is a gastric acyl-peptide that plays an important role in cell 
      proliferation. In the present study, we explored the role of ghrelin in A549 cell 
      proliferation and the possible molecular mechanisms. We found that ghrelin 
      promotes A549 cell proliferation, knockdown of the growth hormone secretagogue 
      receptor (GHSR) attenuated A549 cell proliferation caused by ghrelin. Ghrelin 
      induced the rapid phosphorylation of phosphatidylinositol 3-kinase (PI3K), Akt, 
      ERK, mammalian target of rapamycin (mTOR) and P70S6K. PI3K inhibitor (LY 294002), 
      ERK inhibitor (PD98059) and mTOR inhibitor (Rapamycin) inhibited ghrelin-induced 
      A549 cell proliferation. Moreover, GHSR siRNA inhibited phosphorylation of PI3K, 
      Akt, ERK, mTOR and P70S6K induced by ghrelin. Akt and mTOR/P70S6K phosphorylation 
      was inhibited by LY 294002 but not by PD98059. These results indicate that 
      ghrelin promotes A549 cell proliferation via GHSR-dependent PI3K/Akt/mTOR/P70S6K 
      and ERK signaling pathways.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Zhu, Jianhua
AU  - Zhu J
AD  - Laboratory of Clinical Immunology, Wuhan No. 1 Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology (HUST), Wuhan, Hubei, PR China. 
      Electronic address: zhujh621@163.com.
FAU - Yao, Jianfeng
AU  - Yao J
AD  - Quanzhou Maternal and Child Health Care Hospital, Quanzhou, Fujian, PR China.
FAU - Huang, Rongfu
AU  - Huang R
AD  - The Second Affiliated Hospital, Fujian Medical University, Quanzhou, Fujian, PR 
      China.
FAU - Wang, Yueqin
AU  - Wang Y
AD  - Laboratory of Clinical Immunology, Wuhan No. 1 Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology (HUST), Wuhan, Hubei, PR China.
FAU - Jia, Min
AU  - Jia M
AD  - Laboratory of Clinical Immunology, Wuhan No. 1 Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology (HUST), Wuhan, Hubei, PR China.
FAU - Huang, Yan
AU  - Huang Y
AD  - Laboratory of Clinical Immunology, Wuhan No. 1 Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology (HUST), Wuhan, Hubei, PR China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180310
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Ghrelin)
RN  - 0 (Receptors, Ghrelin)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.1.137 (Phosphatidylinositol 3-Kinase)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (Ribosomal Protein S6 Kinases, 70-kDa)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - A549 Cells
MH  - Carcinoma, Non-Small-Cell Lung/*metabolism/pathology
MH  - *Cell Proliferation
MH  - Ghrelin/*metabolism
MH  - Humans
MH  - Lung Neoplasms/*metabolism/pathology
MH  - MAP Kinase Signaling System
MH  - Phosphatidylinositol 3-Kinase/metabolism
MH  - Phosphorylation
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - Receptors, Ghrelin/metabolism
MH  - Ribosomal Protein S6 Kinases, 70-kDa/metabolism
MH  - *Signal Transduction
MH  - TOR Serine-Threonine Kinases/metabolism
OTO - NOTNLM
OT  - A549 cell
OT  - ERK
OT  - GHSR
OT  - Ghrelin
OT  - PI3K/Akt/mTOR/P70S6K
OT  - Proliferation
EDAT- 2018/03/11 06:00
MHDA- 2018/05/04 06:00
CRDT- 2018/03/11 06:00
PHST- 2018/03/02 00:00 [received]
PHST- 2018/03/06 00:00 [accepted]
PHST- 2018/03/11 06:00 [pubmed]
PHST- 2018/05/04 06:00 [medline]
PHST- 2018/03/11 06:00 [entrez]
AID - S0006-291X(18)30505-9 [pii]
AID - 10.1016/j.bbrc.2018.03.031 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2018 Apr 6;498(3):616-620. doi: 
      10.1016/j.bbrc.2018.03.031. Epub 2018 Mar 10.